NECTIN4 and bladder transitional cell carcinoma: In a similar way, for agents like Enfortumab vedotin, targeting NECTIN-4, which is approved in bladder cancer (BLCA), high expression of this TAA is also observed in the esophagus epithelium (CESC-normal).